Aeste announces its latest data on its new drug enfortumab vedotin in Phase 1 clinical
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, Seattle Genetics and Astellas presented their latest data on thenew drugat the annual meeting of ASCOstudies have shown that this innovative treatment has shown promising results in the treatment of metastatic urinary skin cancerenfortumab vedotinenfortumab vedotin by Seattle Genetics and Astellas is expected to bring good news to bladder cancer patientsenfortumab vedotin is an antibodydrug(ADC) under study, consisting of two parts: a monoclonal antibody that is a common molecule on the surface of a targeted solid tumor, Nectin-4, and a microtube destroyer, MMAEdesigned to identify cancer cells with Nectin-4, enfortumab vedotin can kill them with precisionnot long ago, the U.SFDA(granted enfortumab vedotin breakthrough therapy to treat late-local or metastatic urinoma)studieson urinary skin cancer, in a clinicaltrialcalled EV-101 (enfortumab vedotin showed encouraging results the trial recruited 112 patients, all of whom had metastatic urinary skin cancer and had been treated with chemotherapy studies showed that the overall remission rate of enfortumab vedotin was 41%, with four of them achieving complete remission (3.6%) It is worth noting that of these 112 patients, 89 had previously been treated with immunocheckpoint inhibitors In this patient population, the overall remission rate for this innovative ADC is 40%
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
